Press release or official announcement from a major US cancer treatment center

Valar Labs Secures $22M Series A for AI-Powered Cancer Tool Vesta

May 30, 2024, 04:07 PM

Valar Labs has launched an AI-powered cancer care prediction tool, Vesta, aimed at predicting treatment responses in bladder cancer. The biotech startup secured $22 million in a Series A funding round led by DCVC and a16z. The tool can scan digital histology slices from tumors to predict disease progression and treatment outcomes, potentially saving time for patients. Valar Labs plans to expand the application of this tool to other types of cancer. The company has rolled out its first test and notes that there are roughly 2 million new cancer diagnoses annually in the US alone.